3rd Quarter - Report

AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS for AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS

Firm
Client
Income
—
Expenses
$250,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

H.R. 2245, S. 296, "Preserving Access to Life-Saving Medications Act," all provisions. Contacts concerning Food and Drug Admnistration (FDA) authority to manage drug shortages. Communication to FDA on withdrawal of unapproved drugs, presentation at FDA Public Workshop on drug shortages. Labor-Health and Human Services appropriations, fiscal year 2011; support for Administration's request for FDA funding. Contacts concerning funding for section 3503 of the Affordable Care Act (P.L. 111-148)

LobbyistCovered position, as disclosed
JOSEPH M HILL —
BRIAN M MEYER —
KAREN NOONAN —
CHRISTOPHER J TOPOLESKI —

Contacted: HOUSE OF REPRESENTATIVES; Government Accountability Office (GAO); Health & Human Services, Dept of (HHS); SENATE; Food & Drug Administration (FDA); Health Resources & Services Administration (HRSA); Centers For Medicare and Medicaid Services (CMS)

Bills named: S. 296 (112th), H.R. 2245 (112th)

Medicare/Medicaid MMM

Communication with Centers for Medicare and Medicaid Services regarding hospital outpatient prospective payment system, influenza vaccines, conditions of participation, Innovation Center, funding for specialized pharmacy residency programs, and direct reimbursement under the Medicare program.

LobbyistCovered position, as disclosed
JOSEPH M HILL —
BRIAN M MEYER —
KAREN NOONAN —
CHRISTOPHER J TOPOLESKI —

Contacted: Centers For Medicare and Medicaid Services (CMS); Health Resources & Services Administration (HRSA); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS); Government Accountability Office (GAO)

Pharmacy PHA

Comments to the Health Resources and Services Administration on the 340B Drug Discount Program and the procurement of orphan drugs under the program. Submitted letter of support for H.R. 2674, the 340B Improvement Act of 2011.

LobbyistCovered position, as disclosed
JOSEPH M HILL —
BRIAN M MEYER —
KAREN NOONAN —
CHRISTOPHER J TOPOLESKI —

Contacted: Centers For Medicare and Medicaid Services (CMS); Government Accountability Office (GAO); SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); Health Resources & Services Administration (HRSA)

Bills named: H.R. 2674 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.